Roche announced a definitive agreement to acquire biotech firm 89bio for up to $3.5 billion, acquiring pegozafermin, a promising FGF21 analogue in Phase III trials for moderate to severe metabolic dysfunction-associated steatohepatitis (MASH). The acquisition bolsters Roche’s cardiovascular and metabolic disease portfolio, expanding their pipeline with innovative treatments addressing high unmet needs. Analysts project peak annual sales surpassing $2 billion, highlighting the strategic value of this deal in the growing NASH therapeutic market.